{
    "clinical_study": {
        "@rank": "122509", 
        "acronym": "X-TRAP", 
        "arm_group": {
            "arm_group_label": "Capecitabine and Aflibercept", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The Primary Phase I objectives are to determine the recommended phase II dose for the\n      capecitabine and aflibercept doublet combination; and to describe any dose limiting and\n      non-dose limiting toxicities. The Phase II Primary objective is to determine progression\n      free survival associated with this regimen. The Phase II secondary objectives are to\n      determine response rate associated with this regimen; to determine overall survival\n      associated with this regimen; and to explore any correlation of clinical outcome with\n      baseline and on treatment changes in blood-based angiogenesis biomarkers.\n\n      This open-label, non-randomized phase I/II trial is designed to assess the safety,\n      tolerability and RPTD of capecitabine plus aflibercept in adult subjects with metastatic\n      colorectal cancer."
        }, 
        "brief_title": "Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. For the phase I portion, patients must have histologically and/or cytologically\n             confirmed malignant solid tumor that is refractory to standard therapies.\n\n             For the phase II portion, patients must have histologically and/or cytologically\n             confirmed metastatic colorectal carcinoma that has progressed on, is intolerant of,\n             or is inappropriate for all standard therapies. Subjects must have been treated with\n             a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan\n             and bevacizumab or have contraindication to such treatment. Prior epithelial growth\n             factor receptor (EGFR)-targeting agent (or contraindication to these drugs) is\n             required for subjects with K-Ras wildtype tumors\n\n          2. Measurable disease by RECIST 1.1 criteria (see Appendix 1). Previously irradiated\n             sites can be included if there is documented progression of disease in that site.\n\n          3. Age 18 years and older.\n\n          4. KPS > 70% (see Appendix 2)\n\n          5. Life expectancy > 3 months.\n\n          6. Adequate organ and marrow function as defined below:\n\n               -  Absolute neutrophil count > 1.5 x 109/L\n\n               -  Platelet count > 100 x 109/L\n\n               -  Hemoglobin > 9 g/dl\n\n               -  Total bilirubin  < 1.5 x ULN\n\n               -  AST (SGOT)/ALT (SGPT) < 2.5 x ULN (or <5 x ULN if liver metastases)\n\n               -  Creatinine clearance \u226550 mls/min by Cockcroft-Gault\n\n               -  Urine Protein/Creatinine ratio  < 1 (or protein < 1+ on urinalysis or\n                  24hour urine protein < 1gram/24 hours)\n\n          7. Previous radiotherapy for palliation of recurrent disease is allowed if >4 weeks have\n             elapsed since completion of therapy.\n\n          8. Ability to take oral medications.\n\n          9. Ability to understand and the willingness to sign a written informed consent\n             document.\n\n         10. Women of childbearing potential must have a negative serum pregnancy test within 7\n             days from day 1 of study drug; both men and women must be willing to use two methods\n             of contraception, one of them being a barrier method during the study and for 6\n             months after last study drug administration.\n\n         11. Signed informed consent\n\n        Exclusion Criteria:\n\n          1. Patients currently receiving anticancer therapies or who have received anticancer\n             therapies within 4 weeks from day 1 of study drug (including investigational agents,\n             chemotherapy, radiation therapy, antibody based therapy, etc.)\n\n          2. History of severe hypersensitivity reactions/anaphylaxis attributed to humanized\n             and/or chimeric monoclonal antibodies or other such proteins.\n\n          3. History of significant intolerance to capecitabine or 5FU (ie. Grade 4 toxicity\n             related to one of these agents; grade 3-4 toxicity related to other concurrently\n             administered agents is not an exclusion).\n\n          4. History of abdominal fistula or gastrointestinal perforation at any point within 6\n             months prior to day 1 of study drug, unless surgically repaired.\n\n          5. Active peptic ulcer disease, inflammatory bowel disease (e.g. ulcerative colitis,\n             Crohn's disease), diverticular disease or other gastrointestinal conditions with\n             increased risk of perforation or gastrointestinal bleeding.\n\n          6. Active bleeding diathesis or history of any major bleeding, CNS bleeding, or\n             significant hemoptysis within 6 months of enrollment.\n\n          7. Anticoagulation with warfarin (anticoagulation with low molecular weight heparin is\n             not an exclusion).\n\n          8. History of arterial thromboembolic events or symptomatic pulmonary embolism within 6\n             months of study enrollment.\n\n          9. Poorly controlled hypertension [defined as systolic blood pressure (SBP of >150 mmHg\n             or diastolic blood pressure (DBP) of >90 mmHg]\n\n         10. Patients who have had a major surgery or significant traumatic injury within 4 weeks\n             from day 1 of study drug.\n\n         11. History of active brain metastases or carcinomatous meningitis (treated metastases\n             are permitted, provided the patient is asymptomatic and off steroids for 28 days).\n\n         12. Female patients who are pregnant or breast feeding, or adults of reproductive\n             potential who are not using effective birth control methods. Two acceptable forms of\n             contraceptives must be continued throughout the trial by either sex. Hormonal\n             contraceptives are not acceptable as a sole method of contraception.  (Women of\n             childbearing potential must have a negative serum pregnancy test within 7 days prior\n             to day 1 of study drug).\n\n         13. Any active infection, intercurrent illness, severe acute or chronic medical or\n             psychiatric  condition or laboratory abnormality that may increase the risk\n             associated with study participation or study drug administration, or may interfere\n             with the interpretation of study results, and in the judgment of the investigator\n             would make the patient inappropriate for entry into this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661972", 
            "org_study_id": "Pro00037688"
        }, 
        "intervention": {
            "arm_group_label": "Capecitabine and Aflibercept", 
            "description": "A standard 3+3 dose escalation format will be used. Since each agent is well tolerated as monotherapy and in combination with other chemotherapy regimens, we will start at capecitabine 850mg/m2 to be given days 1-14 and off days 15-21. The dose will then be escalated to 1000mg/m2, given on the same schedule. The dose of aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks. Both agents will be administered on a 21-day cycle. Once the RPTD of the doublet combination has been identified, an additional 50 subjects with metastatic colorectal cancer will be added to a single-arm, Phase II portion for expanded safety, response and biomarker data.", 
            "intervention_name": "Capecitabine and aflibercept", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "colorectal cancer", 
            "all solid tumors", 
            "metastatic", 
            "refractory", 
            "advanced solid tumors"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "link": {
            "description": "Duke Cancer Institute Research programs: Gastrointestinal Cancers - Colorectal cancers and cancers of the stomach, esophagus and other digestive organs", 
            "url": "http://www.dukecancerinstitute.org/research/clinical-trials/trials_for_adult_category/1500"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke Cancer Center, Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "John Strickler, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }, 
                    "name": "Virginia Oncology Associates"
                }, 
                "investigator": {
                    "last_name": "David Z Chang, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "X-TRAP: Phase I/II Study of Capecitabine Plus Aflibercept in Metastatic Colorectal Cancer", 
        "overall_contact": {
            "email": "brant.hamel@duke.edu", 
            "last_name": "Brant Hamel, PhD", 
            "phone": "919-668-1861"
        }, 
        "overall_contact_backup": {
            "email": "anthony.amara@duke.edu", 
            "last_name": "Anthony Amara, MSW", 
            "phone": "919-668-1861"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "John Strickler, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Phase 1 of this study will be the dose escalation component to determine safety and the RPTD for the capecitabine plus aflibercept combination. Dose escalation will begin with cohort 1 and continue as described in the protocol.  RPTD is determined by the dose limiting and non-dose limiting toxicities (Primary obj 2 for Phase I)", 
                "measure": "Recommended Phase II dose (RPTD) for the capecitabine and aflibercept doublet combination", 
                "safety_issue": "Yes", 
                "time_frame": "RPTD for the study will be determined at the completion of Phase I; up to 1 year"
            }, 
            {
                "description": "The primary objective of Phase II is to describe any signs of clinical activity, including response rate and progression free survival in patients with metastatic colorectal cancer.  For the purpose of sample size determination, a patient will be considered to have been successfully treated if the patient remained progression-free 2 months after the administration of the experimental treatment.", 
                "measure": "Progression free survival associated with the regimen", 
                "safety_issue": "No", 
                "time_frame": "2 months progression free"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661972"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Duke University Medical Center", 
            "investigator_full_name": "John Strickler, M.D.", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Response is assessed at restaging, approximately every 9 weeks.  For response, the frequency of best response (CR+PR) to the treatment will be tabulated and its 95% confidence intervals will be computed.", 
                "measure": "Frequency of best response", 
                "safety_issue": "No", 
                "time_frame": "approximately every 9 weeks and/or restaging"
            }, 
            {
                "description": "Overall survival associated with this regimen will be assessed. Subjects will be followed until death which is estimated to be on average 6 months - 1 year after coming off protocol therapy.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Subjects will be followed until death which is estimated to be on average 6 months - 1 year after coming off protocol therapy"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "John Strickler, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}